Perspective Therapeutics, Inc. reported $1.4M of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.4M (to Q4 2024). Net income: −$116M, trailing twelve months to Q2 2027. Free cash flow: −$121M, trailing twelve months to Q2 2027. EPS: −$1.33, trailing twelve months to Q2 2027.

CATXPerspective Therapeutics, Inc.

Healthcare

$1.60-47% 1Y

$1.60

$1.6052 weeks$5.65

Latest close: a new 52-week lowOct 23, 2026what changed →

CATX as reported

Perspective Therapeutics, Inc. reported $1.4M of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed.

$1.4M

Revenue, trailing twelve months · to Q4 2024 · every figure below is as filed, with no scoring applied

Net income: −$116M
Net income · +23% year on year · trailing twelve months to Q2 2027
Free cash flow: −$121M
Free cash flow · +5.6% year on year · trailing twelve months to Q2 2027
EPS: −$1.33
EPS · −2.2% year on year · trailing twelve months to Q2 2027

Details›

Every series Ryufin has for CATX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.4M	n/a	Q4 2024 · 10 quarters behind
Net income	−$116M	+23%	Q2 2027
EPS	−$1.33	−2.2%	Q2 2027
Gross margin	18%	n/a	Q4 2024 · 10 quarters behind
Operating margin	−287%	n/a	Q4 2024 · 10 quarters behind
Net margin	−130%	n/a	Q4 2024 · 10 quarters behind
ROE	−40%	n/a	Q2 2027
ROA	−33%	n/a	Q2 2027
ROIC	−127%	n/a	Q2 2027
Free cash flow	−$121M	+5.6%	Q2 2027

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.